Enterprise Europe Network

Multifunctional nanoparticles for the diagnosis and treatment of cancer

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20200130001
Published
30/01/2020
Last update
17/02/2020
Expiration date
17/02/2021

Keywords

Partner keyword: 
Micro- and Nanotechnology
Cytology, Cancerology, Oncology
Other diagnostic
Therapeutic services
Drug delivery and other equipment
Pharmaceuticals/fine chemicals
EXPRESS YOUR INTEREST

Summary

Summary: 
A research group from a major Spanish university has developed a synthesis method of polymeric multifunctionalized nanoparticles that have the ability to diagnose, treat and monitor different types of cancer. The group is looking for a pharmaceutical company interested in a license agreement of the patented technology.

Description

Description: 

Nowadays, functionalized nanoparticles are opening a wide range of opportunities to improve the diagnosis and treatment of different kind of pathologies.

A research group from a major Spanish university has developed and patented functionalized nanoparticles that are focussed in the integration of diagnosis and therapy in one nanodevice, so called theragnosis. This approach enables the diagnosis together with the treatment and monitoring of the treatment efficiency and disease progress at the same time.

The nanoparticles are conjugated with the following agents:
• A tumour-specific ligand refers to any molecule, particularly any peptide, which is tumour-specific of the tumour to be treated or diagnosed. This ligand is conjugated to the surface of the nanoparticle.
• An imaging tracker refers to any agent that can be used for monitoring the efficacy of the treatment or the diagnosis.
• Drug/s to treat the tumour

Unlike nanoparticles for theragnostic known in the prior art, where the drug and the imaging tracker are heterogeneously encapsulated inside the particle, the controlled multi-functionalization of these new nanoparticles allows tuning the ratio between the amounts of each one of the components: the drug, the ligand and the diagnostic agent. This fact increases dramatically the possibilities of developing more effective nanodevices for controlled released and monitoring in real time.

The university is looking for a pharmaceutical company in order to reach a license agreement for the patented technology.

Advantages & innovations

Cooperation plus value: 
Multifunctional tool: The nanoparticles allow the integration into a single therapeutic agent with the following abilities: - Diagnosis due to the imaging tracker - Treating cancer, thanks to the therapeutic payload - Monitoring the efficacy of the treatment Active tumour-targeting: The tumour-specific ligand increases the retention and accumulation of nanoparticles in the tumour resulting in an efficient and selective internalization in the tumour cells. This allows: - Improvement in the therapeutic efficacy. - Reduction of anticancer drug toxicity. Administering drugs locally rather than systemically (affecting the whole body) is a common way to decrease side effects. Versatile therapeutic agents: The nanoparticles can diagnose and treat different types of cancer by changing the imaging tracker and the drug respectively (personalized medicine). Stable nanoparticles with an efficient cancer cell internalization.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The University is looking for a major pharmaceutical company or alternatively a company specialised in Nanotechnology. The company should have the capacity to develop functionalized nanoparticles.

Type and size

Cooperation task: 
>500 MNE,251-500,SME 51-250,>500